Cargando…

Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase

BACKGROUND: Florid oral papillomatosis is characterized by its tendency to local recurrence that requires multiple treatments, leading to important functional sequelae. METHODS: We present 74‐year‐old woman with oral florid papillomatosis (OFP) who refused a new surgical treatment, and was treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz‐Huertas, Pedro, Borrego‐Luque, Alicia, Toledano‐Valero, Pilar, Manzotti, Carolina, Rollón‐Mayordomo, Ángel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382048/
https://www.ncbi.nlm.nih.gov/pubmed/35416411
http://dx.doi.org/10.1002/cre2.557
_version_ 1784769214850007040
author Ruiz‐Huertas, Pedro
Borrego‐Luque, Alicia
Toledano‐Valero, Pilar
Manzotti, Carolina
Rollón‐Mayordomo, Ángel
author_facet Ruiz‐Huertas, Pedro
Borrego‐Luque, Alicia
Toledano‐Valero, Pilar
Manzotti, Carolina
Rollón‐Mayordomo, Ángel
author_sort Ruiz‐Huertas, Pedro
collection PubMed
description BACKGROUND: Florid oral papillomatosis is characterized by its tendency to local recurrence that requires multiple treatments, leading to important functional sequelae. METHODS: We present 74‐year‐old woman with oral florid papillomatosis (OFP) who refused a new surgical treatment, and was treated with imiquimod 5% in orabase on alternate days for 16 weeks. Treatment was complemented with application of hyaluronic acid gel. RESULTS: There were no side effects to the treatment, nor signs of local recurrence, in the treated area at 2 years of follow‐up. CONCLUSIONS: After reviewing the literature and according to our knowledge, this is the first published case of oral florid papillomatosis treated topically with imiquimod 5% successfully. Topical treatment with imiquimod 5% in orabase may be a valid alternative for patients with recurrent OFP located in the anterior area of the oral cavity who refuse surgical treatment, although we must closely monitor the patient for the possibility of recurrence or malignant degeneration.
format Online
Article
Text
id pubmed-9382048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93820482022-08-19 Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase Ruiz‐Huertas, Pedro Borrego‐Luque, Alicia Toledano‐Valero, Pilar Manzotti, Carolina Rollón‐Mayordomo, Ángel Clin Exp Dent Res Short Communication BACKGROUND: Florid oral papillomatosis is characterized by its tendency to local recurrence that requires multiple treatments, leading to important functional sequelae. METHODS: We present 74‐year‐old woman with oral florid papillomatosis (OFP) who refused a new surgical treatment, and was treated with imiquimod 5% in orabase on alternate days for 16 weeks. Treatment was complemented with application of hyaluronic acid gel. RESULTS: There were no side effects to the treatment, nor signs of local recurrence, in the treated area at 2 years of follow‐up. CONCLUSIONS: After reviewing the literature and according to our knowledge, this is the first published case of oral florid papillomatosis treated topically with imiquimod 5% successfully. Topical treatment with imiquimod 5% in orabase may be a valid alternative for patients with recurrent OFP located in the anterior area of the oral cavity who refuse surgical treatment, although we must closely monitor the patient for the possibility of recurrence or malignant degeneration. John Wiley and Sons Inc. 2022-04-13 /pmc/articles/PMC9382048/ /pubmed/35416411 http://dx.doi.org/10.1002/cre2.557 Text en © 2022 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Ruiz‐Huertas, Pedro
Borrego‐Luque, Alicia
Toledano‐Valero, Pilar
Manzotti, Carolina
Rollón‐Mayordomo, Ángel
Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase
title Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase
title_full Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase
title_fullStr Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase
title_full_unstemmed Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase
title_short Oral florid papillomatosis: Topical treatment with 5% imiquimod in orabase
title_sort oral florid papillomatosis: topical treatment with 5% imiquimod in orabase
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382048/
https://www.ncbi.nlm.nih.gov/pubmed/35416411
http://dx.doi.org/10.1002/cre2.557
work_keys_str_mv AT ruizhuertaspedro oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase
AT borregoluquealicia oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase
AT toledanovaleropilar oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase
AT manzotticarolina oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase
AT rollonmayordomoangel oralfloridpapillomatosistopicaltreatmentwith5imiquimodinorabase